PHAT
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Phathom Pharmaceuticals will present new VOQUEZNA data and analyses at the 2026 American College of Gastroenterology Annual Scientific MeetingOct 8, 2026
- Phathom Pharmaceuticals initiates a registrational Phase 3 trial of VOQUEZNA (vonoprazan) for as-needed treatment of non-erosive GERDSep 30, 2026
- Phathom completed patient enrollment ahead of schedule in the Phase 2 VOQUEZNA study for eosinophilic esophagitisJun 23, 2026
- Phathom confirms 10-year regulatory exclusivity for VOQUEZNA following FDA Orange Book updateJun 16, 2025
- Phathom Pharmaceuticals receives FDA confirmation of 10-year exclusivity for VOQUEZNA® until May 2032Jun 9, 2025